Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib has Kis of L1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC5